Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A.

ABSTRACT:

Objective

To determine whether lutein supplementation will slow visual function decline in patients with retinitis pigmentosa receiving vitamin A.

Design

Randomized, controlled, double-masked trial of 225 nonsmoking patients, aged 18 to 60 years, evaluated over a 4-year interval. Patients received 12 mg of lutein or a control tablet daily. All were given 15,000 IU/d of vitamin A palmitate. Randomization took into account genetic type and baseline serum lutein level.

Main outcome measures

The primary outcome was the total point score for the Humphrey Field Analyzer (HFA) 30-2 program; prespecified secondary outcomes were the total point scores for the 60-4 program and for the 30-2 and 60-4 programs combined, 30-Hz electroretinogram amplitude, and Early Treatment Diabet

SUBMITTER: Berson EL 

PROVIDER: S-EPMC2987594 | biostudies-literature | 2010 Apr

REPOSITORIES: biostudies-literature